Aktiia Bracelet Review: Accuracy, FDA Status, and the Hilo Rebrand

The Aktiia Bracelet taught a wave of wearables to estimate blood pressure without a cuff; it now goes by Hilo, holds an FDA clearance, and is still least certain at night, the hours it was built to watch.

Hand people a free blood pressure monitor, teach them to use it, assign them a navigator who calls and messages, and a large share still will not measure. In a Mass General Brigham remote hypertension program of 3,390 adults with uncontrolled blood pressure, 32.7 percent took no home readings at all at baseline, and the authors concluded that more convenient, less burdensome ways to measure might be needed (JAMA Cardiology, 2026).

The Aktiia Bracelet was built for exactly that failure. It is a cuffless blood pressure monitor made by Aktiia SA of Neuchâtel, Switzerland, that estimates blood pressure from light reflected by the arteries of the wrist, automatically, through the day and night, once you have calibrated it against an upper-arm cuff. In May 2025 the company renamed itself Hilo. The bracelet now sells in Europe and the UK as the Hilo band, and in July 2026 its technology launched in the United States as Hilo Core.

So this review has two jobs: sorting out what the Aktiia name now means and what the FDA cleared, and then judging accuracy. Blood pressure is the main lever on the Silent Assassin, cardiovascular disease, and ischaemic heart disease and stroke remain the two leading causes of death worldwide (Lancet, 2025). An estimate that guides that lever must be judged for one person on one night, not only averaged across a study. On that test the bracelet is impressive in a chair and shakier in bed.

What Is the Aktiia Bracelet, and Is Aktiia Now Hilo?

Yes. Aktiia SA, the Swiss company behind the Aktiia Bracelet, rebranded as Hilo in May 2025 alongside a $42 million Series B round. The bracelet is now sold as the Hilo band in Europe and the UK, while the US version, Hilo Core, launched in July 2026. Same company, same optical approach, new name.

The renaming caused confusion, because the bracelet built its research record under the Aktiia name. Here is the sequence, from peer-reviewed papers, company announcements and trade press:

• 2021: The CE marked bracelet’s validation trial, run with Lausanne University Hospital (NCT04027777), is published.
• March 2021 to March 2023: 32,152 European users generate 668,080 paired wrist and cuff readings (Frontiers in Digital Health, 2025).
• May 2025: Aktiia raises a $42 million Series B and rebrands as Hilo.
• July 2025: The FDA clears Aktiia’s G0 blood pressure monitoring system through the 510(k) pathway (K250415) for over-the-counter use; the company called its Hilo band the first cuffless monitor with that status.
• July 2026: Hilo launches Hilo Core in the United States alongside a $19 million funding extension.

Coverage describing the bracelet as awaiting FDA clearance, including the first version of this review, is out of date. Be precise about the word, though: a 510(k) clearance means the FDA found a device substantially equivalent to one already on the market. It is not an approval. How Hilo labels the US Core band, and which part of that system carries which claim, is a nuance our Hilo Core review walks through in detail.

The science did not change with the name. Every peer-reviewed accuracy study we found was run on the Aktiia Bracelet, and the Hilo products inherit that evidence.

How Does the Aktiia Bracelet Work?

The Aktiia Bracelet shines light into the skin of the wrist and measures how much returns as each heartbeat swells the arteries beneath it. Software checks the signal quality, reads the shape and timing of that pulse wave, produces an uncalibrated estimate, then converts it into millimeters of mercury using cuff readings you take at setup.

Start with the heartbeat. Every contraction of the left ventricle launches a pressure wave down the arterial tree, and when it reaches the wrist the small arteries there swell for a fraction of a second. Blood absorbs light, so the light bouncing back to the bracelet’s sensor dips and recovers in rhythm with the pulse. That flickering trace is a photoplethysmogram, or PPG, the same signal smartwatches use to count heart rate.

Blood pressure is harder to pull out of it. A more pressurized arterial system reshapes the wave: how fast it rises, how it echoes from branching vessels, how it decays. Those features also carry information about age, vessel stiffness, temperature, posture and band tightness. Separating pressure from the rest is the entire problem.

Calibration is how Aktiia handles it. In the company’s 2021 validation trial, the bracelet’s algorithms first ran a signal quality check, then calculated uncalibrated estimates of systolic and diastolic pressure, then translated them into mmHg with a person-specific calibration parameter derived from the first two reference readings (Blood Pressure Monitoring, 2021). Think of it as learning your accent. The optical signal speaks a dialect unique to your arteries; the cuff readings are the dictionary.

The company has also tested whether the light signal contains genuine pressure information or is just age and body size in disguise. Using 668,080 paired readings from 32,152 users, its scientists trained models to flag high blood pressure (140/90 mmHg or above on the cuff). Models built only on demographics and heart rate performed poorly, with an area under the curve below 0.65. A model using the PPG waveform alone reached 0.84 for systolic pressure, and adding demographics raised it to 0.89, with 80 percent sensitivity and 80 percent specificity (Frontiers in Digital Health, 2025). Every author was a company employee, but the result is plausible: the pulse wave does carry a pressure signature. It also means one in five high readings in that test set was missed and one in five normal readings flagged.

Finally, the bracelet measures opportunistically, when the signal is clean; in the company’s study of older adults, 83 percent of paired measurements passed its quality filter (Blood Pressure, 2023). You get many readings without effort, but not one on demand.

How Accurate Is the Aktiia Bracelet? What the Research Shows

On average, accurate; for individuals, variable. In the company’s 2021 validation trial of 86 adults, seated readings differed from trained human observers by 0.46 mmHg systolic on average, with a standard deviation of 7.75 mmHg. Precision worsened in other postures, and independent studies show the widest gaps at night.

The Company Trials

The pivotal trial enrolled adults aged 21 to 65 and followed them for one month, comparing the bracelet against double-blinded auscultation by two trained observers, the classic stethoscope method, in the seated position. In the 86 participants analyzed, the mean difference was 0.46 ± 7.75 mmHg for systolic pressure and 0.39 ± 6.86 mmHg for diastolic. The authors reported that the device satisfied both accuracy criteria of an extended version of the ISO 81060-2:2013 standard while seated, across the full month after initialization (Blood Pressure Monitoring, 2021).

The same trial, published with 91 recruited participants in Scientific Reports, reported what happened when people moved. Systolic differences were -2.44 ± 10.15 mmHg lying down and -0.62 ± 12.51 mmHg standing; diastolic standing readings were off by -4.85 ± 9.11 mmHg. The authors, Aktiia employees working with Lausanne University Hospital clinicians, wrote that precision varies across positions and that the bracelet’s prognostic value for cardiovascular events would need longitudinal studies (Scientific Reports, 2021).

A follow-up in 35 adults aged 65 to 85 without diabetes found a similar pattern across 469 paired measurements: systolic differences of 1.23 ± 7.88 mmHg seated, -1.81 ± 11.11 mmHg standing, and -1.8 ± 9.96 mmHg lying, with standing diastolic readings off by -5.35 ± 7.75 mmHg. The authors used modified ISO criteria because, as they noted, no universal standard for cuffless devices existed at the time (Blood Pressure, 2023).

Read the second number in each pair. A mean error near zero says the bracelet is not systematically high or low across a group; the standard deviation says how far a single reading strays. If errors follow a roughly normal distribution, a standard deviation of 12.51 mmHg means about one standing reading in three misses the reference by more than 12 mmHg. That is enough to move a person across a treatment threshold in either direction.

Independent Studies and the Night Problem

The bracelet’s most distinctive promise is the night. Home cuffs cannot measure you asleep, ambulatory cuffs do it by inflating through the night, and the company’s own researchers wrote that the strongest predictor of cardiovascular risk comes from night measurements (Scientific Reports, 2021). That is precisely where independent data are least reassuring.

The clearest test comes from Pilsen, in the Czech Republic. Researchers fitted 21 children with well-controlled type 1 diabetes with both the Aktiia bracelet and a conventional 24-hour ambulatory cuff at the same time. Averaged over 24 hours, the bracelet read 4.5 mmHg lower for systolic and 0.8 mmHg lower for diastolic pressure, close enough at the group level. But the limits of agreement for individuals were wide, especially for systolic pressure, and the normal nighttime dip in blood pressure was blunted on the bracelet. The authors concluded it should not be considered interchangeable with ambulatory monitoring for individual clinical decisions or for judging nocturnal dipping (Journal of Hypertension, 2026).

A Swiss case report tells the same story in a higher-stakes setting. A pregnant woman with a history of severe preeclampsia wore the bracelet through her second pregnancy alongside three 24-hour ambulatory sessions. Daytime averages were comparable; nighttime readings differed significantly. The authors stressed that cuffless devices have yet to be validated in pregnancy (Blood Pressure, 2025). In a feasibility study of 10 people with sleep apnea on CPAP, nocturnal blood pressure data quality varied with technical issues and individual factors, and two participants dropped out, one over skin allergies and one because the device interfered with work (Frontiers in Sleep, 2025).

In a German pilot, pharmacists guided 10 adults with previously elevated readings through 14 days with the Aktiia/Hilo bracelet; six were above the 135/85 mmHg 24-hour threshold and got their results to discuss with other clinicians (Frontiers in Cardiovascular Medicine, 2026). That illustrates the intended use, a longer look that prompts follow-up, but with no reference device it does not test accuracy.

Two notes for close readers. A 2025 24-hour comparison in the European Heart Journal: Digital Health that reported poor agreement is listed by PubMed as a retracted publication, so we have not relied on it. And Queen Mary University of London has completed recruitment for Continuum BP, a randomized crossover study in 48 adults comparing the Aktiia Bracelet and a second wrist device against cuffed 24-hour monitoring; results were not yet published at its 2026 design paper (American Heart Journal Plus, 2026).

What Hypertension Experts Say

The European Society of Hypertension’s working group stated in 2022 that recent European guidelines do not recommend cuffless devices for diagnosing or managing hypertension, and that validation protocols written for cuff devices are inadequate for cuffless ones. The open questions it listed fit the Aktiia exactly: dependence on individual calibration, stability after calibration, and the ability to track real changes in pressure (Journal of Hypertension, 2022). A 2021 review in Hypertension made the sharper point that the 2018 universal validation standard for automated cuffs is inappropriate for cuffless devices, and that many published accuracy studies use inadequate methods (Hypertension, 2021).

Why does that matter? A calibrated device can look excellent in a test where blood pressure never moves, because it only has to repeat its baseline. The real question is whether it tracks pressure up with exercise, down after medication, and down at night. In 2023 the society published six validation tests built for cuffless devices, covering static accuracy, arm position, treatment-induced drops, awake to asleep changes, exercise, and recalibration stability (Journal of Hypertension, 2023). The Aktiia studies we reviewed used adapted versions of the cuff standard rather than that full six-test protocol. A 2026 scientific statement in the European Journal of Preventive Cardiology still does not recommend cuffless devices for clinical decisions, despite their potential (European Journal of Preventive Cardiology, 2026). Our explainer on what “clinically validated” actually means covers why passing one protocol is not the same as being fit for every purpose.

What the Aktiia Bracelet Gets Right

It removes the ritual. Passive measurement captures readings when people would never reach for a cuff, including during sleep, and builds a pattern from many readings rather than a verdict from one. Its maker also published more peer-reviewed data than most cuffless rivals, and it now holds an FDA clearance.

It attacks the adherence gap. A third of supported patients in the Mass General Brigham program took no readings at the start. A bracelet that measures without being asked sidesteps that. Whether passive data change outcomes is unproven.

It favors patterns over snapshots. Blood pressure is not a fixed number; it moves with sleep, stress, meals, and posture. When a leading hypertension researcher wore five devices at once for 24 hours, including a wrist band, a chest patch and a ring alongside validated cuffs on both arms, none captured blood pressure perfectly, and she argued the habit of judging people on a single clinic measurement should itself be revisited (Journal of Human Hypertension, 2024). The Aktiia is built around that idea.

It has a real evidence trail. When Australian researchers catalogued 532 wrist-band blood pressure wearables sold online, none had been validated (Hypertension, 2020). The Aktiia is in a different class: peer-reviewed studies, a registered trial, a large real-world dataset, and growing independent research.

It is honest about calibration, and regulators reviewed it. Rather than claiming to read pressure from light alone, it anchors to cuff readings, and it holds CE marking plus a 2025 FDA clearance, more than most wearables showing blood pressure numbers can say.

Where the Aktiia Bracelet Falls Short

Precision for individuals, especially lying down, standing, and asleep. The supporting evidence is largely company co-authored, uses adapted cuff-device protocols that experts consider inadequate for cuffless devices, and does not show that wearing it improves health outcomes. It also still needs a cuff, so it never fully escapes the ritual.

Individual precision. Standard deviations of 10 to 12.5 mmHg lying and standing, in the company’s own trials, are wide for a number people may act on. The averages are reassuring; any single reading is not.

The night. The feature that most distinguishes the device is the one independent studies question most: blunted nocturnal dipping in children, significant night differences in pregnancy, and variable overnight data quality in sleep apnea.

Who did the research. The pivotal trials had Aktiia employees as authors, and the 32,152-user analysis was written entirely by company staff. That does not make the results wrong, but it makes independent replication essential.

Who was studied. The pivotal trial covered ages 21 to 65; the older-adult study excluded people with diabetes; pregnancy is unvalidated; pediatric data come from 21 children with type 1 diabetes. If you fall outside those groups, the evidence speaks to you less directly.

The cuff dependency. In the trial, trained observers calibrated the device. At home, your own cuff technique does, and a rushed calibration reading becomes the baseline for every later estimate.

No outcome data. No study we found shows that wearing the bracelet lowers blood pressure or prevents heart attacks or strokes. The broader evidence on self-monitoring is sobering: in an individual patient data meta-analysis of randomized trials, self-monitoring alone produced no significant change in clinic systolic pressure at 12 months (-1.0 mmHg), while self-monitoring combined with intensive support, such as clinician or pharmacist medication adjustment, lowered it by 6.1 mmHg (PLoS Medicine, 2017). Data do not treat anything. People do.

Aktiia Bracelet vs Hilo Core vs Signal Ring vs Withings BPM Connect

Choose by job. A validated upper-arm cuff like the Withings BPM Connect gives the number a clinician will act on. The Aktiia Bracelet (Hilo band) and Hilo Core add passive day and night trends anchored by a cuff. Signal Ring promises cuffless readings with no calibration at all, a bolder claim with no peer-reviewed evidence we could find.

Feature	Aktiia Bracelet (now Hilo band)	Hilo Core (US)	Signal Ring	Withings BPM Connect
How it measures	Optical sensor at the wrist	Optical wrist band in a hybrid system with an upper-arm cuff	Optical sensor in a finger ring	Inflating upper-arm cuff
Cuff calibration	Yes; EU and UK bundles include the calibration cuff	Yes; cuff is part of the system	Company says no cuff or calibration needed	Not applicable; it is the cuff
Regulatory status (October 2026)	CE marked; FDA 510(k) cleared for over-the-counter use, July 2025	Built on the G0 system cleared in July 2025; see our review for how the US band is labeled	No FDA clearance found in our search	FDA cleared and CE marked
Peer-reviewed accuracy evidence	Several studies, mostly company co-authored; independent data show wider individual error	Relies on the Aktiia studies; no Core-specific trial found	None found in PubMed	Passed ISO 81060-2:2018 twice (2022); on the AMA validated device list
Readings during sleep	Yes, passive	Yes, background trends	Marketed as continuous monitoring	No
Price	Varies by country	Hardware plus subscription	$399 at its July 2026 launch	$99.95 on Withings’ US store

Hilo Core is the Aktiia approach repackaged for the US: a screenless optical band, an upper-arm cuff, and an app that turns readings into patterns. In the United States, this is the version you can buy.

Signal Ring, from the startup Vital Signals, went the other way: a $399 ring that its maker says needs no cuff and no calibration. That would solve the Aktiia’s biggest practical weakness if it holds up, but it is the hardest version of the problem, and as of October 2026 we found no peer-reviewed validation of it in PubMed. Our Signal Ring review covers its company-reported study figures and what remains unproven.

The Withings BPM Connect is the conservative baseline: a validated Wi-Fi upper-arm cuff. Our Withings BPM Connect review explains why that validation matters more than any app feature. Many people will be best served by owning a validated cuff whether or not they also wear a bracelet.

Nearby options: a wrist cuff watch in our Omron HeartGuide review, and clinical cuffless monitoring in our Biobeat BB-613 review.

How Much Does the Aktiia Bracelet Cost, and Is It Covered or HSA/FSA Eligible?

As of October 2026 there is no current Aktiia-branded price, because the product sells as the Hilo band in Europe and the UK, bundled with a calibration cuff, and as Hilo Core in the US with a subscription. We could not verify current European prices, HSA or FSA eligibility for the bracelet itself, or any insurance coverage for this review.

The previous version of this page quoted an Aktiia hardware price plus a monthly subscription. We could not confirm those figures from a current source, so we removed them. In Europe or the UK, check Hilo’s regional store, where the Hilo band is listed with its calibration cuff.

For US buyers, the product is Hilo Core, and the subscription is central to the model. Our Hilo Core review covers the US hardware price, subscription cost, what happens if you cancel, and HSA and FSA status.

For perspective, the validated Withings BPM Connect cuff sells for $99.95 on Withings’ US store with no required subscription. We found no evidence that insurers routinely cover cuffless wrist monitors; if your clinician needs ambulatory data for a diagnosis, the standard route is a prescribed 24-hour cuff study.

Who Should Use the Aktiia Bracelet, and Who Should Skip It?

Use it if you want a low-effort picture of how your blood pressure moves across days and nights, and you will treat what it shows as a prompt rather than a diagnosis. Skip it if you are pregnant, need readings to guide medication, or simply want one trustworthy number; a validated cuff does that better.

Good fit:

• Adults who keep abandoning home cuff monitoring and want effortless measurement.
• People curious how sleep, stress, alcohol or exercise move their numbers, who will confirm anything concerning with a cuff.
• Patients whose clinician or pharmacist welcomes trend data as context.

Skip it, or talk to your clinician first:

• Pregnancy, including any history of preeclampsia; cuffless devices are not validated in pregnancy.
• Children, outside of research settings.
• Anyone whose medication is being adjusted on the basis of home readings; those decisions belong to validated cuff or ambulatory measurements.
• People who find noisy health data stressful.
• Anyone with symptoms such as chest pain, severe headache, or sudden weakness. Seek urgent care rather than checking a wearable.

A clinician who treats hypertension can tell you which monitoring your situation calls for; the Healthcare Discovery doctor directory can help.

What This Means for You

Blood pressure is the most modifiable lever on the Silent Assassin, and any tool that gets you measuring helps. But the lever moves through what you do with the numbers: sleep, movement, nutrition, breath, and a clinician who confirms and treats. The bracelet can show patterns; it cannot pull the lever.

In a Lancet meta-analysis of 123 trials with 613,815 participants, every 10 mmHg reduction in systolic pressure cut major cardiovascular events by 20 percent, stroke by 27 percent and all-cause mortality by 13 percent (Lancet, 2016). Those gains came from lowering pressure, not measuring it.

That is where the Five Pillars come in. Sleep is where the bracelet is most interesting and least certain: if it suggests your pressure fails to fall at night, ask about a proper 24-hour ambulatory study. Nutrition is a lever many people never pull; an Australian position statement recommends that patients with hypertension who add salt switch to potassium-enriched salt unless at risk of high potassium (Journal of Hypertension, 2025). Movement, Breath and Mindset shape the daily swings a wearable reveals; the point of seeing them is to change them.

A practical protocol if you buy one: take calibration seriously, seated, rested, with the arm supported and the cuff at heart height; look at weekly averages rather than single readings; confirm any persistent high pattern with a validated upper-arm cuff; and bring both to your clinician. For the bigger picture of how high blood pressure fits into heart attack, stroke, dementia and metabolic disease risk, read our guide to the Four Villains of Health and Longevity, and browse our cardiology device reviews for the full field of cuffs, watches and patches.

The Aktiia Bracelet showed that light at the wrist carries a real blood pressure signal. Under its new name it is a useful window on patterns, not yet a number to bet your treatment on. Use it as a reason to look closer.

Frequently Asked Questions

Sources

1. Unlu O, et al. Patient engagement with home blood pressure monitoring. JAMA Cardiology, 2026. DOI
2. GBD 2023 Causes of Death Collaborators. Global burden of 292 causes of death in 204 countries and territories, 1990 to 2023. Lancet, 2025. DOI
3. Vybornova A, et al. Blood pressure from the optical Aktiia Bracelet: a 1-month validation study using an extended ISO81060-2 protocol adapted for a cuffless wrist device. Blood Pressure Monitoring, 2021. DOI
4. Sola J, et al. Validation of the optical Aktiia bracelet in different body positions for the persistent monitoring of blood pressure. Scientific Reports, 2021. DOI
5. Theiler, et al. Performance of the Aktiia optical blood pressure measurement device in the elderly: a comparison with double blinded auscultation in different body positions. Blood Pressure, 2023. DOI
6. Sola J, et al. The quest for blood pressure markers in photoplethysmography and its applications in digital health. Frontiers in Digital Health, 2025. DOI
7. Huml M, et al. Continual cuffless blood pressure monitoring in children: agreement and feasibility compared with ambulatory blood pressure monitoring. Journal of Hypertension, 2026. DOI
8. Gassmann, et al. Case report: use of a cuffless blood pressure monitoring device compared to ambulatory blood pressure monitoring in a pregnant patient. Blood Pressure, 2025. DOI
9. Hediger-Parolini A, et al. Remote monitoring of patients with obstructive sleep apnea syndrome treated with CPAP: a feasibility study. Frontiers in Sleep, 2025. DOI
10. Schlottau S, et al. Continuous assessment and research on enhanced blood pressure control: CareBP study. Frontiers in Cardiovascular Medicine, 2026. DOI
11. Bhatt, et al. Validation of a popular consumer-grade cuffless blood pressure device for continuous 24 h monitoring. European Heart Journal: Digital Health, 2025. Listed by PubMed as a retracted publication; findings not used. DOI
12. Gupta AK, et al. A randomized crossover clinical trial comparing 24-h blood pressure measurements from two different cuffless wrist ambulatory monitors with cuffed ambulatory monitoring: rationale and design of Continuum BP study. American Heart Journal Plus, 2026. DOI
13. Stergiou GS, et al. Cuffless blood pressure measuring devices: review and statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. Journal of Hypertension, 2022. DOI
14. Mukkamala R, et al. Evaluation of the accuracy of cuffless blood pressure measurement devices: challenges and proposals. Hypertension, 2021. DOI
15. Stergiou GS, et al. European Society of Hypertension recommendations for the validation of cuffless blood pressure measuring devices. Journal of Hypertension, 2023. DOI
16. Parati G, et al. Cuffless blood pressure monitoring devices: technical foundations and clinical implications. European Journal of Preventive Cardiology, 2026. DOI
17. Schutte AE. Wearable cuffless blood pressure tracking: when will they be good enough? Journal of Human Hypertension, 2024. DOI
18. Picone DS, et al. Nonvalidated home blood pressure devices dominate the online marketplace in Australia: major implications for cardiovascular risk management. Hypertension, 2020. DOI
19. Tucker KL, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLoS Medicine, 2017. DOI
20. Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, 2016. DOI
21. Xu X, et al. Potassium-enriched salt for patients with hypertension: a Hypertension Australia and National Hypertension Taskforce of Australia position statement. Journal of Hypertension, 2025. DOI
22. Hilo. Aktiia raises $42M in Series B and becomes Hilo. Company announcement, May 2025. Hilo
23. Molten Ventures. Aktiia secures $42 million in Series B funding round; rebrands to Hilo. 2025. Molten Ventures
24. Aktiia. Aktiia’s Hilo band becomes first cuffless blood pressure monitor cleared by FDA for over-the-counter use. Press release via BioSpace, July 2025. BioSpace
25. MassDevice. FDA clears Aktiia over-the-counter G0 cuffless blood pressure monitor. July 2025. MassDevice
26. HLTH. Hilo launches blood pressure monitoring system in the U.S. July 2026. HLTH
27. MobiHealthNews. Hilo launches blood pressure tracker with $19M funding boost. July 2026. MobiHealthNews
28. Hilo. Hilo band (includes calibration cuff). UK product page. Hilo
29. Vital Signals. Signal Ring unveils world’s first truly cuffless blood pressure tracker for everyday wear. Press release, July 2026. Fitt Insider
30. Pulse 2.0. Signal Ring launches $399 cuffless blood pressure wearable. July 2026. Pulse 2.0